Many of these genes are well-established as key players in osteogenesis or skeletal development, such as FOSL2, which controls osteoclast size and survival [23]; WWTR1 (TAZ), encoding a key member of the Hippo pathway that interacts with RUNX2 to induce osteogenesis [24]; SLC9A3R1 (NHERF), a member of the Wnt signaling pathway associated with hypophosphatemic nephrolithiasis/osteoporosis-2 (OMIM 612287) as well as low bone mineral density [25]; and TGFB1, mutations in which lead to Camurati-Engelmann disease (OMIM 131300) and bone density alterations [26]. The gene discussed is NHERF1; the disease is Camurati-Engelmann disease.